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Summary Broad-spectrum neuropeptide growth factor antagonists, such as [D-Arg', D-Phe5, D-Trp7'9,
Leu']substance P (antagonist D) and [Arg6, D-Trp7'9, NmePhe8]substance p(6-11) (antagonist G), are currently
being investigated as possible anti-tumour agents. These compounds are hoped to be effective against
neuropeptide-driven cancers such as small-cell lung cancer. Antagonist D possesses a broader antagonistic
spectrum than antagonist G and hence may be of greater therapeutic use. The in vitro metabolism of antagonist
D has been characterised and the structures of two major metabolites have been elucidated by amino acid
analysis and mass spectrometry. Metabolism was confined to the C-terminus where serine carboxypeptidase
action produced [deamidated]-antagonist D (metabolite 1) and [des-Leu' ]-antagonist D (metabolite 2) as the
major metabolites. Biological characterisation of the metabolites demonstrated that these relatively minor
changes in structure resulted in a loss of antagonist activity. These results provide some of the first structure-
activity information on the factors that determine which neuropeptides these compounds inhibit and on the
relative potency of that inhibition.
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Successful, long-term treatment of small-cell lung cancer
(SCLC) remains a major therapeutic problem. Despite 70-
80% of patients initially responding to conventional
chemotherapy, the survival rate at 5 years is lower than
5% (Everard et al., 1993). The disease is characterised by its
ability to secrete and to be growth stimulated by a variety of
neuropeptide growth factors that include bombesin/gastrin-
releasing peptide (GRP), vasopressin, bradykinin, cholecys-
tokinin and neurotensin (Woll and Rozengut, 1989).
Interruption of this complex growth-stimulatory network
has been shown to be effective against SCLC both in vitro
and in vivo by several workers (Mahmoud et al., 1991;
Thomas et al., 1992; Davis et al., 1992; Langdon et al., 1992;
Kelly et al., 1993). A series of analogues based initially on the
structure of substance P has been demonstrated to possess
broad-spectrum activity and they are capable ofinhibiting the
effects of multiple neuropeptides. These agents include [D-
Arg'-D-Phe5-D-Trp7'9-Leu' 1]-substance P and [Arg6-D-Trp7'9-
NmePhe8]-substance P(6-11) (code named antagonists D and
G respectively) (Sethi et al., 1992).
Antagonists D and G have been shown to inhibit the
growth of SCLC xenografts (WX322 and H69) in nude mice
(Langdon et al., 1992). Antagonist D is equipotent to
antagonist G against SCLC cells in vitro and has been
shown to be a 10-fold more potent inhibitor of bombesin and
bradykinin (Woll and Rozengurt, 1988). Antagonist D has
been reported to induce apoptosis in both SCLC and non-
SCLC cell lines in vitro (Reeve and Bleehan, 1994), to have
activity against other SCLC xenografts (HC12 and ICR-
SCl 12) in vivo (Everard et al., 1993) and to have in vitro
activity against non-SCLC, ovarian and cervical cancer cell
lines (Everard et al., 1992). In the near future antagonist G
will be the first of this new class of compound, broad-
spectrum neuropeptide growth factor antagonists, to enter a
phase I clinical trial for the potential treatment of SCLC.
Given its broader spectrum of activity, antagonist D may
represent another member of this class with greater potential
for becoming a useful new agent for the treatment of cancer.
The research reported here describes the characterisation
of the in vitro metabolism of antagonist D, comparing its
metabolic stability to that of antagonist G, which we have
previously reported (Jones et al., 1995). The metabolites have
been purified and their structures elucidated by mass
spectrometry and amino acid analysis. The neuropeptide
antagonist properties of the major metabolites have also been
studied and this data, along with the enzymology of the
metabolism, has strong structure-activity implications.
Materials and methods
Antagonist D was purchased from Peninsula Laboratories (St
Helens, UK), Antagonist G was supplied by Peptech
(Europe) (Copenhagen, Denmark). H-D-Arg-Pro-Lys-Pro-D-
Phe-Gln-D-Trp-Phe-D-Trp-Leu-Leu-OH (metabolite 1) and
H-D-Arg-Pro-Lys-Pro-D-Phe-Gln-D-Trp-Phe-D-Trp-Leu-OH
(metabolite 2) were prepared in-house using conventional
Fmoc solid-phase peptide synthesis procediures. Reagents for
peptide synthesis were purchased from NovaBiochem (UK)
(Nottingham, UK). Acetic acid and ammonium acetate were
from BDH Chemicals (Poole, UK). Methanol and acetoni-
trile were high-performance liquid chromatography (HPLC)
grade from Rathburn Chemicals (Walkerburn, UK). Tri-
fluoroacetic acid was from Sigma Chemical (Poole, UK). All
other chemicals Were of the highest grade commercially
available and used without further purification. Water was
deionised and bidistilled in a quartz glass still.
HPLC
The HPLC system used consisted of two 510 HPLC pumps, a
712 WISP autosampler, a TCM column heater (all Waters,
Northwich, UK) and a model 1046A fluorescence detector
(Hewlett Packard, Walborn, Germany). A Waters MAXIMA
820 computer package was used with a Waters system
interface module to control the system operation and collect
and integrate data. Separation was achieved on a Prime-
sphere 5 gm (250 x 4.6 mm) column (Phenomenex, Maccles-
field, UK) using isocratic elution with 45% (v/v) acetonitrile
in 0.1% (v/v) aqueous triflouroacetic acid (TFA) at 450C.
Detection of the peptides was by fluorescence (Excitation
233 nm Emission 395 nm). Quantitation was by external
standard.
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In vitro production and isolation of the metabolites of
antagonist D
Mouse liver was homogenised in phosphate-buffered saline
(PBS; pH 7.4; 10% solution w/v) to a final concentration of
2% w/v liver. To 10 ml of this homogenate was added 1.0 ml
of PBS containing 1.2 mg of antagonist D. The mixture was
incubated at 37°C for 2 h before 10 ml of methanol-0.1%
aqueous TFA- I M ammonium acetate (80: 10:10, v/v/v) was
added followed by vigorous vortexing. The resultant mixture
was centrifuged at 800 g for 10 min. Antagonist D and its
metabolites were isolated from the supernatant via solid-
phase extraction (SPE). The SPE procedure used was a
modified protocol to that previously described (Cummings et
al., 1994) using a 3 cm3 (200 mg sorbent) C8 Bond-Elut
column (Varian Sample Preparation Products, Harbour City,
CA, USA). The 3 cm3 Bond-Elut column was activated with
methanol (7 ml), washed with distilled water (7 ml) and the
sample applied in 1.0 ml aliquots. When all the sample had
been applied the column was washed with water (10 ml) and
allowed to air dry for 60 min. Antagonist D and its
metabolites were eluted with 10 ml of methanol-0.1%
aqueous TFA -I M ammonium acetate (80:10:10, v/v/v)
and the eluted solution concentrated to a final volume of
2.0 ml in a UNIVAP (Uniscience, London, UK) at 30°C. The
metabolites were purified by reverse-phase HPLC on a CB8
jiBondapak semiprep column (19 x 300 mm; Waters). Separa-
tion was achieved on the chromatography system described
earlier using an isocratic elution buffer consisting of 40%
(v/v) acetonitrile in 0.1% (v/v) aqueous TFA at ambient
room temperature and a flow rate of 3.0 ml min-'.
Amino acid analysis
The amino acid composition of the metabolites was
determined by employing the Waters AccQ.Tag Chemistry
Package (Waters, Northwich, UK). The reagents and
procedure used have been described in detail in the literature
(Cohen et al., 1993). The identity of the amino acids present
in the hydrolysed peptide was determined by external
calibration of the system with a known amino acid mixture
and quantitation was based on comparison with the quantity
obtained after hydrolysing a known amount of standard
antagonist D.
Positive ion fast atom bombardment (FAB) mass
spectrometric analysis
Purified metabolites were mass analysed by Mr A Taylor
(Department of Chemistry, University of Edinburgh, UK) on
a Kratos MS50 TC Mass Spectometer. The samples were
dissolved in a thioglycerol-based matrix and subjected to
static FAB using argon gas (99.99% purity).
Stability ofantagonist D and antagonist G in 1% (w/v) mouse
liver homogenate
Mouse liver was homogenised in PBS, (pH 7.4, 10% solution
w/v) to a final concentration of 1% w/v liver. To 1.0 ml of
the homogenate was added 50 nmol of the antagonist and the
mixture incubated at 37°C. At preselected time points, 0.1 ml
of the incubation mixture was removed and added to 0.4 ml
of 1.0 M acetic acid. This solution was vortexed thoroughly
and then centrifuged at maximum speed in a bench-top
Eppendorf centrifuge for 2 min. An aliquot of 0.2 ml of the
resultant supernatant was then analysed on the HPLC system
described above.
Effect ofphenylmethylsulfonylfluoride (PMSF) on the in vitro
metabolism of antagonist D
Degradation of antagonist D (100 jg) in 1.0 ml of 2% (w/v)
mouse liver homogenate in PBS at 37°C was studied in the
presence of increasing concentrations of PMSF ranging
between 0 and 2.5 mM. Where PMSF was to be present it
was preincubated with the liver homogenate for 15 min at
23°C before the addition of antagonist D. At the appropriate
time points, 0.1 ml of the incubation mixture was withdrawn
and added to 0.9 ml of 1.0 M acetic acid. This sample was
vortexed vigorously for 1 min before being centrifuged in an
Eppendorf bench-top centrifuge at maximum speed for
2 min. An aliquot of 0.2 ml of the resultant supernatant
was analysed by HPLC as described above.
In vitro biological activity of antagonist D and its major
metabolites
Confluent, quiescent cultures of Swiss 3T3 cells in 33 mm3
nunc plates were washed twice with Dulbecco's modified
Eagle medium (DMEM) and incubated in a humidified
atmosphere of 10% carbon dioxide at 37°C with DMEM/
Waymouth's medium (1:1 v/v) containing [3H]thymidine
(0.25 ,uCi ml-', 1 jM), insulin (1 jig ml-'), neuropeptide
growth factor (either bombesin, vasopressin or bradykinin,
1 nM) and various concentrations of antagonist D or its
metabolites. After 40 h, the cultures were washed twice with
PBS and incubated in 5% trichloroacetic acid (TCA) at 40°C
for 30 min to remove acid-soluble radioactivity. Cultures
were washed with industrial grade ethanol, solubilised in
1.0 ml of 2% sodium hydrogen carbonate, 0.1 M sodium
hydroxide, 1% sodium dodecyl sulphate and the radioactivity
in the subsequent acid-soluble fraction was determined by
scintillation counting in 6.0 ml Ultima Gold (Packard).
Results
Detection and isolation of the metabolites ofantagonist D
Under optimal chromatographic conditions it has proved
possible to separate antagonist D from two major metabolites
(Figure 1) produced in vitro by incubation with 2% w/v
mouse liver homogenate. The metabolites were named on the
basis of their chromatographic similarity to the parent
peptide, which eluted with a retention time of 11.14 min.
The metabolites detected were metabolite 1 (retention time =
11.63 min) and metabolite 2 (retention time = 6.83 min). A
minor metabolite peak was also seen with a retention time of
8.83 min, but it was not present in sufficient quantities to
facilitate its purification and characterisation. These two
metabolites were purified to single peaks on HPLC and
subjected to extensive chemical and biochemical analysis to
determine their structure and biological activity.
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Figure 1 RP-HPLC of extracted mixture of antagonist D and its
metabolites using isocratic elution after isolation by solid-phase
extraction from 2% (w/v) mouse liver homogenate in PBS at 37°C
for 2h.
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uTable I Amino acid analysis
Amino acid Standard antag D Metabolite 1 Metabolite 2
Glutamate 1.00 0.79 0.89
Arginine 1.00 0.88 1.04
Proline 2.00 2.03 1.90
Lysine 1.00 0.92 0.99
Leucine 2.00 1.94 1.07
Phenylalanine 2.00 1.93 1.44
Amino acid analysis
The purified metabolites were hydrolysed for 2 h at 150°C
before precolumn derivatisation and separation by reversed-
phase HPLC. The basis of detecting the residues present was
fluorescence, which is problematic when tryptophan is
involved, since UV detection is more suitable (Cohen et al.,
1993). Consequently, the residues one would expect to detect
when analysing antagonist D and its metabolites are
phenylalanine, leucine, lysine, proline, arginine and glutamic
acid (produced by deamidation of the side-chain amide of
glutamine during the acid hydrolysis). This was confirmed
when hydrolysing a known standard of antagonist D. The
results of the amino acid analysis are summarised in Table I.
Metabolite 1 contained all the same residues as antagonist D,
indicating that hydrolysis of a peptide-bond had not occurred
to produce this metabolite, but some other modification was
responsible for the change in the chromatography compared
with the parent peptide. Metabolite 2, although containing all
the same residues as antagonist D, did show a reduction in
the amount of leucine detected. This would indicate that
metabolism has removed the C-terminal leucine, yielding H-
D-Arg-Pro-Lys-Pro-D-Phe-Gln-D-Trp-Phe-D-Trp-Leu-OH.
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Figure 2 Degradation of antagonist D and antagonist G in 1%
mouse liver homogenate. Values are expressed in nmol detected
after correcting for extraction efficiencies of 94.4% and 94% for
antagonists D and G respectively. (y-error bars represent the
standard deviation from three experiments). -D-, Antagonist
D; -O-, antagonist G.
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FAB mass spectrometric analysis
Mass analysis of the two metabolites and standard antagonist
D was performed and the protonated species detected
([M+H]+) confirmed the results seen in the amino acid
analysis. A nominal mass of 1404 was obtained for
metabolite 2, which corresponds to the expected m/z for H-
D-Arg-Pro-Lys-Pro-D-Phe-Gln-D-Trp-Phe-D-Trp-Leu-OH.
The masses detected for metabolite 1 and standard antagonist
D were, in part, not as expected. Although protonated
molecules were detected at 1517 and 1516 respectively, a
more significant mass was detected at one mass unit higher in
each case. This result was consistent in multiple analyses,
including analysis of the synthetic standards, and is most
likely due to each molecule becoming di-protonated under
these analytical conditions. The increase of one mass unit
between metabolite 1 (m/z 1517) and parent antagonist D
(m/z 1516) can be explained by conversion from a peptide-
amide to a peptide-acid. Further evidence for this having
happened was obtained by the addition of ionic sodium to
the matrix. No detectable difference was observed with
standard antagonist D, but a 22 4uM shift in the m/z value
of metabolite 1 produced a protonated molecule with an m/z
of 1539, a result suggesting the formation of the sodium salt
of the peptide-acid. It was therefore concluded that the
structure of metabolite 1 was H-D-Arg-Pro-Lys-Pro-D-Phe-
Gln-D-Trp-Phe-D-Trp-Leu-Leu-OH. Metabolite 1 and meta-
bolite 2 also co-eluted under HPLC with the respective
standards, which had been synthesised using conventional
Fmoc chemistry and manual solid-phase peptide synthesis.
Stability of antagonist D and antagonist G in mouse liver
homogenate
As seen in Figure 2, antagonist D was significantly more
stable than antagonist G when 50 nmol were incubated in
mouse liver homogenate, after 1 h of incubation there was
still 30.8 nmol of antagonist D remaining compared with
21.1 nmol of antagonist G. Antagonist D disappeared at half
the rate of antagonist G over the first 30 min and the route
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Figure 3 Rate of accumulation of the major metabolites of
antagonist G and antagonist D in 1% mouse liver homogenate.
An extraction efficiency of 94.4% was assumed for antagonist D
metabolites and 94% for antagonist G metabolites. The values are
the means of three experiments and variation between replicate
values did not exceed + 5%.
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Figure 4 Effect of phenylmethylsulfonylfluoride (PMSF) on the
degradation of antagonist D in vitro. Antagonist D (100l g) was
incubated at 37°C in 2% mouse liver homogenate in PBS (1.Oml)
in the presence of varying mm concentrations of PMSF. The
results shown are the mean of between two and four experiments
where variation in the inhibition observed never exceeded 10% in
any duplicate sample.
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Figure 5 Effect of increasing concentrations of peptide
antagonist on the uptake of [3H]thymidine by Swiss 3T3 cells
following mitogenic stimulation by bombesin (1 nM). Results
shown are the mean ofduplicate samples where variation between
samples did not exceed + 5%.
of metabolism appears to be the same in both cases in that it
is the C-terminus that is degraded by deamidation and
carboxypeptidase action. When comparing the flux of
metabolites in each case (Figure 3), it is apparent that
deamidation is a much more prominent pathway for
antagonist G than antagonist D. After 1 h, 26.2 nmol of
deamidated G had accumulated compared with 9.6 nmol of
deamidated antagonist D (metabolite 1). In contrast, the
carboxypeptidase removal of the C-terminal residue is much
more pronounced with antagonist D with 12.3 nmol of [des-
leucinel-antagonist D accumulating in an hour compared
with no accumulation of [des-methionine]-antagonist G.
Effect ofphenylmethylsulfonylfluoride (PMSF)
Metabolism of antagonist D appears to occur exclusively at
the C-terminus via deamidation and carboxypeptidase action.
Serine carboxypeptidases are the most common class of
enzyme reported to be active in the deamidation of peptide
substrates and confirmation that this type of enzyme is
responsible for the metabolism of antagonist D was gained
by studying the effect of PMSF, a known serine-protease
inhibitor. The in vitro degradation of antagonist D was
inhibited by PMSF in a dose-dependent manner with 1.0 mM
PMSF being sufficient to cause almost complete arrest of the
metabolism (Figure 4).
In vitro biological activity of the metabolites
To establish whether the major metabolites of antagonist D
retained the broad-spectrum neuropeptide antagonist proper-
ties, the synthetic peptides corresponding to metabolite 1
(deamidated antagonist D) and metabolite 2 ([des-Leu"]-
antagonist D) were tested in vitro for their ability to inhibit
the uptake of [3H]thymidine by murine Swiss 3T3 cells that
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Figure 6 Effect of increasing concentrations of peptide
antagonist on the uptake of [3H]thymidine by Swiss 3T3 cells
following mitogenic stimulation by vasopressin (1 nM). Results
shown are the mean of duplicate samples where variation between
samples did not exceed + 5%.
Figure 7 Effect of increasing concentrations of peptide
antagonist on the uptake of [3H]thymidine by Swiss 3T3 cells
following mitogenic stimulation by bradykin (1 nM). Results
shown are the mean of duplicate samples where variation
between samples did not exceed + 5%.
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H-D-Arg-Pro-Lys-Pro-D-Phe-GIn-D-Trp-Phe-D-Trp-Leu-Leu-NH2
(antagonist D)
H-D-Arg-Pro-Lys-Pro-D-Phe-Gln-D-Trp-Phe-D-Trp-Leu-Leu-OH
(metabolite 1)
H-D-Arg-Pro-Lys-Pro-D-Phe-Gln-D-Trp-Phe-D-Trp-Leu-OH
(metabolite 2)
Figure 8 Pathway of metabolism of antagonist D.
had been stimulated by either bombesin, vasopressin or
bradykinin, three mitogens known to be antagonised by the
parent peptide. The metabolites retained none of the
antagonist properties of antagonist D with respect to
bombesin (Figure 5) or bradykinin (Figure 6). When the
effects on vasopressin stimulated growth were studied (Figure
7) there was a clear difference between the two metabolites.
Metabolite 1 was inactive whereas metabolite 2 did possess
vasopressin antagonist activity and gave half-maximal
inhibition at 4.0 glM compared with an IC5s value of
< I pM for antagonist D.
Discussion
The broader spectrum of antagonist activity possessed by
antagonist D ([D-Arg'-D-Phe5-D-Trp7 9-Leu1 ']-substance P)
relative to antagonist G ([Arg6-D-Trp7'9-NmePhe8]-substance
p(6-11) may suggest that this compound has greater potential
as a therapeutic agent against SCLC as it inhibits a wider
variety of the neuropeptide growth factors known to be
growth stimulatory in the disease. It was thought that the
increased spectrum of activity of antagonist D was due to the
extended N-terminus that is not possessed by antagonist G,
however one would expect the longer peptide to contain more
sites of peptidase action and therefore be metabolically less
stable. The proposed mode of action of these compounds
relies on them being present in competitive concentrations for
prolonged periods and hence greater metabolic stability
would be advantageous. It has previously been reported
that antagonist D is stable in human plasma, suggesting that,
unlike substance P and the closely related substance P
analogue Spantide, it is a poor substrate for dipepti-
dyl(amino)peptidase IV (DAP IV; EC 3.4.14.5) (Cummings
et al., 1994). In peripheral tissues, substance P has been
shown to be converted to predominantly N-terminal
fragments by such enzymes as angiotensin-converting
enzyme and neutral endopeptidase 24.11 (Van Breeman et
al., 1991). The chemical modifications within the C-terminal
segment of antagonist D would be expected to provide some
degree of protection against such peptidases (Wormser et al.,
1990). If this were the case then the stability of antagonist D
would be far greater than one would have predicted.
The successful purification and characterisation of the
metabolites of antagonist D has allowed the elucidation of
the metabolic pathway followed by this broad-spectrum
neuropeptide antagonist. The pathway of metabolism is
summarised in Figure 8. The route of degradation shows a
great deal of similarity to that which we reported for
antagonist G in that peptidase action is confined to the C-
terminus producing two major metabolites (Jones et al.,
1995), the deamidated product, H-D-Arg-Pro-Lys-Pro-D-Phe-
Gln-D-Trp-Phe-D-Trp-Leu-Leu-OH (metabolite 1) and in
greater quantity the product of carboxypeptidase action,
H-D -Arg
- Pro-Lys-Pro-D-Phe-Gln-D-Trp-Phe-D-Trp-Leu-OH
(metabolite 2). Few enzymes have been reported as being
capable of deamidating peptides, serine carboxypeptidases
being the most common class of enzyme shown to possess
this ability along with the ability to effect removal of the
complete C-terminal amino acid-amide (Jackman et al.,
1990). It was this class of enzyme that was found to be
active in the metabolism of antagonist G (Jones et al., 1995)
and it appears that the same is true in the degradation of
antagonist D as the degradation was inhibited by PMSF, a
known inhibitor of serine proteases, in a dose-dependent
manner (Figure 4).
When comparing the stability of antagonist D and
antagonist G (Figure 2), it can be seen that antagonist D is
almost twice as stable as antagonist G with a lesser degree of
deamidation occurring. The difference in the degree of
deamidase and carboxypeptidase activity observed with
antagonist D and antagonist G (Figure 3) could be due to
the preference of the enzyme for a particular C-terminal
residue with respect to deamidation/decarboxylation. How-
ever, when the deamidase activity of serine carboxypeptidases
was first reported, there appeared to be no such discrimina-
tion between peptides possessing a C-terminal methionine-
amide or leucine-amide and both were readily deamidated at
pH 7.0 (Jackman et al., 1990). It seems unlikely that the
length of the peptide chain is the determining factor in this
differential processing since Jackman and co-workers also
demonstrated that peptide length had little effect on activity
for peptides ranging in length between 11 amino acids
(substance P) and 5 amino acids (D-Ala2-Leu5-enkephalin-
amide). It is possible that the presence of the extended N-
terminal region of antagonist D is having a profound effect
on the conformation of the C-terminal portion of the peptide
that leads to it being recognised differently by the same
enzyme. If such a conformational difference does exist, this
may explain the different affinities of these two broad-
spectrum antagonists for the various neuropeptide receptors
with which they interact. This theory is supported by
evidence that reduction of the C-terminal peptide bond,
which alters the conformation in that region, causes an
increase in the binding affinity of some short-chain bombesin
analogues at the bombesin receptor (Jensen and Coy, 1991).
The biological activity of the metabolites compared with
the parent peptide further indicates that it is the structure at
the C-terminus that is important in determining the spectrum
of antagonist activity. The bombesin and bradykinin
receptors appear more selective in the C-terminal structure
permitted for an antagonist since both deamidation and
carboxypeptidase removal of the leucine-amide residue of
antagonist D produced a dramatic decrease in the antagonist
potency at these receptors. It could be speculated that
development of more potent broad-spectrum antagonists
may be possible by slight modifications of the C-terminus
such as the modifications employed in the development of
bombesin antagonists possessing activity in the nanomolar
range (Jensen and Coy, 1991). Interaction with the
vasopressin receptor may require slightly different aspects of
antagonist structure. Deamidation of antagonist D abolished
its activity against vasopressin in similar manner to the
results with bombesin and bradykinin. However, complete
removal of the C-terminal leucine-amide residue was better
tolerated and there was a less significant shift in the dose-
response curve of metabolite 2 against vasopressin. This
greater flexibility in C-terminal function recognised by the
vasopressin receptor may not have been unexpected in view
of the previous results demonstrating that metabolism of the
C-terminus of antagonist G does not remove vasopressin
antagonist activity (Jones et al., 1995).
In conclusion, the elucidation of the metabolic pathway of
antagonist D and the biological characterisation of its major
metabolites has provided some of the first indications of the
structural requirements for broad-spectrum growth factor
antagonist activity in this class of compounds. It appears
likely that differences in the primary and secondary structure
at the C-terminus of the peptide antagonist has a marked
effect on both the breadth of neuropeptides antagonised and
on the relative potency of these compounds against those
neuropeptides.
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